Hepatitis Test Solution Diagnosis Market Scenario
Hepatitis Test Solution Diagnosis Market is expected to grow significantly over the forecast period. It is anticipated that the market held a value of USD 3233.89 Million in 2030 and is projected to register a 3.86% CAGR over the forecast period.
Globally, there are approximately 71 million individuals that are chronically infected with the hepatitis C virus (HCV). The increasing participation of the regulatory agencies and health care associations towards the testing/diagnosis and treatments of the hepatitis is driving the global market. In 2018, the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, published a guideline for testing, managing, and treating hepatitis C. Various other factors such as the rise prevalence hepatitis, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drugs manufacturers are boosting the market growth.
However, complicated testing and diagnosis process and the side-effects of medication may hamper market growth over the forecast period.
Segmentation
Hepatitis Test Solution Diagnosis Market is segmented based on disease type, type of technology, end user, and region.
Based on disease type, the hepatitis test solution diagnosis market is further segmented into hepatitis A, hepatitis B, hepatitis C, and others.
Based on the type of technology, the hepatitis test solution diagnosis industry at the global level is segmented into nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests (RDT), chemiluminescence immunoassay (CLIA), genotyping, and others.
Based on end-user, the global market is segmented into hospitals, clinics, diagnostic laboratories, blood banks, research institutes, and others
The segments mentioned above are covered under four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The hepatitis test solution diagnosis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European hepatitis test solution diagnosis market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The hepatitis test solution diagnosis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hepatitis test solution diagnosis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Hepatitis Test Solution Diagnosis Market Share (%), by Region, 2018 聽
Sources: MRFR Analysis
The Americas dominated the hepatitis test solution diagnosis industry, owing to the increasing number of patients that are diagnosed with hepatitis, annually. In the Latin America and Caribbean countries, currently, around 9 million people are anti-hepatitis C virus (HCV) positive.
Europe is expected to be the second-largest region in the hepatitis test solution diagnosis industry, owing to the growing detection of hepatitis virus cases in the region.
The market in Asia-Pacific (APAC) is expected to grow significantly owing to the rising prevalence of hepatitis genotypes. Various clinical studies are being carried out. For instance, studies related to the Genotype 1b were done to understand the body鈥檚 response to the hepatitis virus.
Thus, the hepatitis test solution diagnosis market in APAC is expected to hold the third-largest share during the forecast period.
The Middle East & Africa is expected to hold the least share of the hepatitis test solution diagnosis market during the forecast due to the slow economic development, especially in Africa.
Key Players
Some of the Key Players operating in the Hepatitis Test Solution Diagnosis Market are聽Abbott, Biom茅rieux Sa, Bio-Rad Laboratories, Inc., Danaher, DiaSorin S.p.A., Miraca Holdings Inc. (Fujirebio, Inc.), Grifols, Onsite Lab Holding AG (MedMira, Inc.), Qiagen, Roche Holding AG (Roche Diagnostics), Siemens (Siemens Healthineers), and Sandoz International GmbH.
Market Segmentation
Hepatitis Test Solution Diagnosis Market,聽by Disease聽Type
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Others
Hepatitis Test Solution Diagnosis Market,聽by聽Type of Technology
- Nucleic Acid Testing (NAT)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Rapid Diagnostic Tests (RDT)
- Chemiluminescence Immunoassay (CLIA)
- Genotyping
- Others
Hepatitis Test Solution Diagnosis Market,聽by End User
- Hospitals
- Diagnostic Laboratories
- Blood Banks
- Research institutes
- Others
Intended Audience
- Pharmaceutical companies
- Government and private laboratories
- Research and development (R&D) companies
- Research laboratories
- Market research and consulting service providers
|
Report Attribute/Metric
|
Details
|
|
聽聽Market Size
|
聽聽USD 3233.89 Million (2030)
|
|
聽聽CAGR
|
聽聽3.86% (2022-2030)
|
|
聽聽Base Year
|
聽聽2021
|
|
聽聽Forecast Period
|
聽聽2022-2030
|
|
聽聽Historical Data
|
聽聽2020
|
|
聽聽Forecast Units
|
聽聽Value (USD Million)
|
|
聽聽Report Coverage
|
聽聽Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
聽聽Segments Covered
|
聽聽disease type, type of technology, end user, and region
|
|
聽聽Geographies Covered
|
聽聽North America, Europe, Asia-Pacific, and Rest of the World (RoW)
|
|
聽聽Key Vendors
|
聽聽Abbott, Biom茅rieux Sa, Bio-Rad Laboratories, Inc., Danaher, DiaSorin S.p.A., Miraca Holdings Inc. (Fujirebio, Inc.), Grifols, Onsite Lab Holding AG (MedMira, Inc.), Qiagen, Roche Holding AG (Roche Diagnostics), Siemens (Siemens Healthineers), and Sandoz International GmbH.
|
|
聽聽Key Market Opportunities
|
路聽 The rise prevalence hepatitis.
路聽 Increasing Geriatric Population.
路聽 Growing participation of generic drugs manufacturers.
|
|
聽聽Key Market Drivers
|
路聽 The increasing participation of the regulatory agencies.
路聽 Health Care associations towards the testing
|
聽
Hepatitis Test Solution Diagnosis Market Highlights:
Frequently Asked Questions (FAQ) :
The market was valued at more than USD 3233.89 million in 2030
The market is expected to exhibit a strong 3.86% CAGR over the forecast period from 2022 to 2030.
The rise in the prevalence of hepatitis is likely to be the major driver for the market.
The Americas hold a dominant share in the global market of more than 45%.
Leading players in the market include Abbott, Miraca, Danaher, and Roche, among others.
